Abiopharma

🔍 Porter Jeffrey H (Director)

Company: cbdMD, Inc. (YCBD)

Report Date: 2026-04-14

Detailed Transactions and Holdings:

• Acquired 1,572 shares of Common Stock (Direct)
  Date: 2026-04-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,144.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-14 | Code: H | nature_of_ownership: By Porter Partners L.P. | shares_owned_after: 465,955.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-14 | Code: H | nature_of_ownership: By Ben Joseph Partners | shares_owned_after: 61,750.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-14 | Code: H | nature_of_ownership: By Jeff Porter IRA-Beneficiary | shares_owned_after: 41,275.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-14 | Code: H | nature_of_ownership: By Beneficiary of Trust | shares_owned_after: 4,550.00 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The restricted stock units vest quarterly on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027. The restricted stock units were issued under the 2021 or 2025 Equity Compensation Plan as compensation to the Reporting Person for services on the Issuer's Board of Directors.
• F2: Represents shares of common stock held by an entity for which the Reporting Person holds voting and dispositive control.